| Previous Close | 0.24 |
| Open | 0.21 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 0.11 - 0.23 |
| 52 Week Range | 0.02 - 6.49 |
| Volume | 255,898,781 |
| Avg. Volume | 68,694,600 |
| Market Cap | 26.86M |
| Beta | 1.47 |
| PE Ratio (TTM) | -0.07 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investopedia•3 months ago
Delcath Clinical Study Design Approved By FDA
The FDA approved the design of Delcath's clinical trial for its Melphalan HDS chemo delivery product.
- 24/7 Wall St.•6 months ago
DryShips, Merrimack Tumble into Friday’s 52-Week Low Club
DryShips, Merrimack Pharma, Gevo, Delcath Systems post new 52-week lows Friday.
Capital Cube•7 months agoDelcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Categories: Yahoo Finance Get free summary analysis Delcath Systems, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Delcath Systems, Inc. – AngioDynamics, Inc., Insulet Corporation, ICU Medical, Inc., Merit Medical Systems, Inc., Tandem Diabetes Care, Inc., Baxter International Inc. and Teleflex Incorporated (ANGO-US, PODD-US, ICUI-US, ... Read more (Read more...)